A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphoma
Phase 1
Recruiting
- Conditions
- relapsed/refractory CD20 positive B-cell lymphoma
- Registration Number
- JPRN-UMIN000014072
- Lead Sponsor
- Department of Hematology, Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with active infections 2. Patients with severe complications 3. Pregnant or lactating women 4. Patients with history of severe allergy 5. Patients medicated with the immunosuppressive agents 6. Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety: Evaluation by NCI-CTCAE ver 4.0
- Secondary Outcome Measures
Name Time Method Efficacy: Clinical response rate